Keyword: Institute of Biomedicine

This page displays contents related to the keyword.

Artificial intelligence and research use of health data: the computational biology conference ECCB tackles current issues

17.09.2024

How can sensitive health data be used responsibly in scientific research or how can artificial intelligence help make breakthroughs in medical research? The ECCB2024 conference brings together current themes in computational biology and international researchers in Turku, Finland. 

New and crucial role discovered for a protein in the body's immunity against cancer

14.06.2024

Researchers at the University of Turku in Finland have found a new function for an existing protein. They discovered that TIMP-1, a protein traditionally known to prevent damage to the body's cells and tissues, plays a critical role in the immune system's defence against cancer. The findings of the study could improve the effectiveness of current cancer immunotherapies.

Europe’s main computational biology conference comes to Turku, Finland

18.04.2024

Discoveries made when biology meets computational sciences are revolutionising the landscape of life sciences and healthcare. Computational biology and bioinformatics are driving this transformation, helping researchers analyse vast amounts of biological data. European Conference on Computational Biology (ECCB) is Europe’s main event in computational biology and bioinformatics this year, bringing 600–800 experts to Turku, Finland, on 16–20 September 2024.

Docent of Clinical Microbiology Antti Hakanen awarded Docent of the Year recognition at the Academic Day of Turku universities

22.03.2024

At the joint Academic Day of the University of Turku and Åbo Akademi University on 22 March 2024, Antti Hakanen, the Docent of Clinical Microbiology at the University of Turku and the Chief of Department at Tyks Laboratories of the Wellbeing Services County of Southwest Finland, was presented with the Docent of the Year recognition.

New drug developed for melanoma and lung cancer shows potential in treatment of cutaneous squamous cell carcinoma

22.11.2023

Cutaneous squamous cell carcinoma (cSCC), also known as the squamous cell carcinoma of the skin, is the most common form of metastatic skin cancer. The incidence of cSCC is increasing worldwide with millions of new cases diagnosed each year. The prognosis of metastatic cSCC is poor as there are currently no effective targeted treatments available. New study conducted at the University of Turku, Finland, shows that plixorafenib, a new drug developed for treating melanoma and lung cancer, can also stop the progression of cutaneous squamous cell carcinoma.